We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Vericiguat (Verquvo) for the Treatment of Heart Failure.
- Authors
Elmes, Abigail T.; Hellenbart, Erika L.
- Abstract
Vericiguat (Verquvo) is labeled for the treatment of adults with symptomatic chronic heart failure (HF) and an ejection fraction of less than 45%. It is used to reduce the composite risk of cardiovascular death and HF-related hospitalization following a previous hospitalization for HF or the need for outpatient intravenous diuretics.1 Vericiguat causes smooth muscle relaxation and vasodilation by stimulating soluble guanylate cyclase (which is decreased in HF), both independently and synergistically with nitric oxide, a unique mechanism. Vericiguat (Verquvo) is labeled for the treatment of adults with symptomatic chronic heart failure (HF) and an ejection fraction of less than 45%. It is used to reduce the composite risk of cardiovascular death and HF-related hospitalization following a previous hospitalization for HF or the need for outpatient intravenous diuretics. 1 Vericiguat causes smooth muscle relaxation and vasodilation by stimulating soluble guanylate cyclase (which is decreased in HF), both independently and synergistically with nitric oxide, a unique mechanism.
- Subjects
HETEROCYCLIC compounds; STROKE volume (Cardiac output); HEART failure
- Publication
American Family Physician, 2022, Vol 106, Issue 5, p582
- ISSN
0002-838X
- Publication type
Product Review